CervoMed Inc (CRVO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 44.41 is considered Overvalued compared with the five-year average of -5.70. The fair price of CervoMed Inc (CRVO) is between 0.60 to 2.28 according to relative valuation method. Compared to the current price of 3.87 USD , CervoMed Inc By Overvalued By 69.91%.

Relative Value

Fair Zone

0.60-2.28

Current Price：3.87

69.91%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is CervoMed Inc (CRVO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

CervoMed Inc (CRVO) has a current Price-to-Book (P/B) ratio of 2.77. Compared to its 3-year average P/B ratio of 5.58, the current P/B ratio is approximately -50.36% higher. Relative to its 5-year average P/B ratio of 5.58, the current P/B ratio is about -50.36% higher. CervoMed Inc (CRVO) has a Forward Free Cash Flow (FCF) yield of approximately -34.58%. Compared to its 3-year average FCF yield of -21.15%, the current FCF yield is approximately 63.48% lower. Relative to its 5-year average FCF yield of -21.15%, the current FCF yield is about 63.48% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRVO competitors is 8.99, providing a benchmark for relative valuation. CervoMed Inc Corp (CRVO.O) exhibits a P/S ratio of 44.41, which is 394.18% above the industry average. Given its robust revenue growth of -83.37%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRVO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRVO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRVO currently overvalued or undervalued?

What is CervoMed Inc (CRVO) fair value?

CRVO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CervoMed Inc (CRVO) is between 0.60 to 2.28 according to relative valuation method.

How does CRVO's valuation metrics compare to the industry average?

The average P/S ratio for CRVO's competitors is 8.99, providing a benchmark for relative valuation. CervoMed Inc Corp (CRVO) exhibits a P/S ratio of 44.41, which is 394.18% above the industry average. Given its robust revenue growth of -83.37%, this premium appears unsustainable.

What is the current P/B ratio for CervoMed Inc (CRVO) as of Mar 03 2026?

As of Mar 03 2026, CervoMed Inc (CRVO) has a P/B ratio of 2.77. This indicates that the market values CRVO at 2.77 times its book value.

What is the current FCF Yield for CervoMed Inc (CRVO) as of Mar 03 2026?

As of Mar 03 2026, CervoMed Inc (CRVO) has a FCF Yield of -34.58%. This means that for every dollar of CervoMed Inc's market capitalization, the company generates -34.58 cents in free cash flow.

What is the current Forward P/E ratio for CervoMed Inc (CRVO) as of Mar 03 2026?

As of Mar 03 2026, CervoMed Inc (CRVO) has a Forward P/E ratio of -3.46. This means the market is willing to pay $-3.46 for every dollar of CervoMed Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CervoMed Inc (CRVO) as of Mar 03 2026?

As of Mar 03 2026, CervoMed Inc (CRVO) has a Forward P/S ratio of 44.41. This means the market is valuing CRVO at $44.41 for every dollar of expected revenue over the next 12 months.

CRVO Valuation